摘　要：人类糖脂转运结构域2蛋白（GLTPD2）是糖脂转运蛋白（GLTP）家族的一个新成员。本研究的目的在于通过生物信息学分析，探究GLTPD2在肝细胞癌（LIHC）中的表达及临床意义。利用TCGA数据库的第三方在线工具LinkedOmics分析GLTPD2的表达与LIHC各临床病理特征的关系；利用Ualcan工具分析GLTPD2在LIHC中mRNA的表达情况；利用Kaplan-Meier Plotter数据库、GEPIA数据、Oncolnc数据库评估GLTPD2在LIHC中对生存率的影响；利用Timer 2.0数据库分析GLTPD2与肿瘤免疫细胞浸润水平的相关性；通过Metascape网站对GLTPD2及其共表达基因进行功能富集分析，并预测其生物学功能；构建和使用列线图估计LIHC预后。结果表明，GLTPD2在LIHC中低表达，并对LIHC患者的各临床病理特征、免疫细胞浸润水平、患者生存率及预后具有影响。GLTPD2在LIHC中异常表达，并与LIHC的发生、发展密切相关，可能成为LIHC的潜在生物标志物，对LIHC的早期诊断、基因靶向治疗及预后评估具有重要意义。
关键词：肝癌；GLTPD2；生物标志物；预后；生物信息学
中图分类号： Q811.4                            文献标志码：ADOI：10.3969/j.issn.1007-7146.2022.01.005

Abstract: Human glycolipid transfer protein domain containing 2 (GLTPD2) is a new member of the glycolipid transfer protein family (GLTP). The purpose of this study is to explore the expression and clinical significance of GLTPD2 in liver hepatocellular carcinoma (LIHC) through bioinformatics analysis. The third-party online LinkedOmics tool of TCGA database was used to analyze the relationship between GLTPD2 expression and various clinicopathological features of LIHC. Ualcan tool was used to analyze the mRNA expression of GLTPD2 in LIHC. Kaplan-Meier Plotter database, GEPIA data and Oncolnc database were used to evaluate the effect of GLTPD2 on survival in LIHC, and Timer 2.0 database was used to analyze the correlation between GLTPD2 and tumor immune cell invasion level. Metascape conducted functional enrichment analysis of GLTPD2 and its co-expressed genes, and predicted its biological function, and constructed and used for LIHC cancer prognosis. The results showed that GLTPD2 expression was low in LIHC, and affected the clinicopathological features, immune cell infiltration level, survival rate and prognosis of patients with LIHC. GLTPD2 is abnormally expressed in LIHC and is closely related to the initiation and progression of LIHC, which may be used as a potential biomarker of LIHC, and was of important implication for the early diagnosis, gene targeted therapy and prognosis evaluation of LIHC.
Key words: liver hepatocellular carcinoma; GLTPD2; biomarker; prognosis; bioinformatics analysis
（Acta Laser Biology Sinica, 2022, 31(1): 027-035）